InnoCAT

Company Overview

Snapshot

Founded in February 2021 by Yishai Ben David, InnoCAT operates with 1–10 employees. The company has secured funding across two rounds, including a grant from the Israel Innovation Authority in January 2024.

Business overview

InnoCAT is developing a wearable electromechanical device for insulin delivery, aiming to simplify diabetes management and enhance patient comfort and safety. Its proprietary pump architecture integrates user-centric design with efficient electromechanical components to ensure high wearability, usability, and reliability. The company focuses on manufacturability and cost efficiency to achieve a low cost of goods and scalable production, serving the Health Tech & Life Sciences sector, particularly in Pharma & Medical Biotechnology and Medical Devices, with a focus on Drug Delivery and Medical Treatment & Therapeutics for patients.

Company Intelligence Q&A

What is InnoCAT's core product?

InnoCAT develops a wearable electromechanical device for insulin delivery, designed to simplify diabetes management and improve patient comfort and safety.

When was InnoCAT founded?

InnoCAT was founded in February 2021.

Who is the founder of InnoCAT?

Yishai Ben David is the founder of InnoCAT.

Has InnoCAT received any grants?

Yes, InnoCAT secured a grant from the Israel Innovation Authority in January 2024.

What is InnoCAT's business model?

InnoCAT's business model is built around profitability through design simplicity and streamlined assembly processes, partnering with medical device manufacturers to deliver a sustainable and commercially viable insulin pump.